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Testosterone/Androgens
Comment on: Comparative safety of testoster-
one dosage forms. JB Layton, CR Meier, JL
Sharpless, T Sturmer, SS Jick, MA Brookhart.
JAMA Intern Med 2015;175(7):1187–96.
Testosterone use continues to increase despite
ongoing controversy regarding the potential car-
diovascular risks of therapy, which was highlighted
in a randomized trial of testosterone gels in older
men that demonstrated increased cardiovascular
events [1]. This possibility of increased cardiovas-
cular risk with testosterone replacement therapy
(TRT) has been a continued debate, where several
manuscripts published in high impact factor jour-
nals demonstrated increased risk [2,3], and other
studies have failed to demonstrate this risk as
reality [4,5].
As each delivery mechanism posses varying
pharmacokinetics, it is possible that one therapy
may potentially carry a higher risk than the others.
Injection therapy has been shown to cause a spike
in testosterone level after administration, but the
use of either a transdermal patch or gel imparts a
more subtle increase [6]. In a new-user multi-
cohort comparison study of the use of testosterone
injection, gel, and patch, Layton and colleagues
found that injection initiators had higher hazards
of cardiovascular events when compared with tes-
tosterone gel use [7]. These analyses were con-
ducted on three different cohorts of men,
including a group of commercially insured men
based in the U.S., a Medicare group from the U.S.,
and a compilation of general practitioner medical
records from the U.K.. Patient databases were
queried for outcomes to include myocardial infarc-
tion (MI), unstable angina, stroke, composite acute
events (including MI, unstable angina, or stroke),
all-cause hospitalization, mortality, and venous
thromboembolism (VTE) that were recorded for
up to 1 year after documented initiation of TRT. A
total of 544,115 testosterone initiators were ana-
lyzed between the 3 cohorts where 55.8% of the
patients received gel, 37.4% received injections,
and 6.9% were on a patch. As expected, the
reported incidence of cardiovascular events over 1
year was low among the younger privately insured
US and UK populations when compared with the
older aged Medicare sample. Injection initiators
had higher hazards of cardiovascular events (ie,
MI, unstable angina, and stroke) (1.26; 1.18–1.35),
hospitalization (1.16; 1.13–1.19), and death
(1.34;1.15–1.56) but not VTE (0.92; 0.76–1.11)
when compared with gel initiators. Compared
with gels, patches did not confer increased hazards
of cardiovascular events (1.10; 0.94–1.29), hospi-
talization (1.04; 1.00–1.08), death (1.02; 0.77–
1.33), or VTE (1.08; 0.79–1.47).
As the authors mentioned, this study is limited
based on use of nonrandomized secondary health-
care data. Some of the data sets utilized also lacked
to incorporate signiﬁcant known risk factors of
cardiovascular disease. More so, many patients
that were included in the study were initiated on
TRT without recorded serum testosterone tests or
relevant diagnoses, thus, contaminating the popu-
lation. Despite the possibility that cardiovascular
risk may be increased relatively soon after TRT
initiation [8], the 1 year follow up analyzed in this
study is most likely too short to detect the long-
term cardiovascular effects of testosterone via
altering lipid levels. Based on the nature of the
review, patients receiving in ofﬁce injection
therapy were more likely to be compliant with
injections when compared with men who received
prescriptions of a patch or gel, as the database
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cannot account for what prescriptions were ﬁlled
or used. This study provides good insight that high
peaking serum levels of testosterone may poten-
tially increase cardiovascular risks; however, ran-
domized trials regarding the safety of testosterone
among users compared with nonusers of the drug
are needed.
Theodore R. Saitz, MD
Department of Urology
Oregon Health & Science University
Portland, OR, USA
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Comment on: Association between use of
exogenous testosterone therapy (eTT) and
risk of venous-thrombotic-events among
eTT-treated and untreated men with
hypogonadism. H Li, K Benoit, W Wang, S
Motsko. J Urol 2015 Oct; Epub ahead of print.
A change in drug labeling of all approved testos-
terone products enforced by the Food and Drug
Administration in 2014 required a general warning
regarding the potential increased risk of venous
thromboembolism (VTE) [1]. This prompted a
study, funded by Eli Lilly and Company, that pro-
vided a retrospective cohort analysis of over
200,000 patients and a case-control analysis
including 2,785 cases and 11,119 controls [2]. Ret-
rospective cohort analysis revealed a HR of 1.08
for all eTT-treated patients (95% conﬁdence
interval [CI]: 0.91, 1.27; P = 0.378). Case-control
analysis found an odds ratio [OR] = 1.02 (95% CI:
0.92, 1.13; P = 0.702) for current eTT exposure
and 0.92 (95% CI: 0.82, 1.03; P = 0.145) for past
eTT exposure. Thus, it was concluded there was
no signiﬁcant association between eTT and inci-
dents of idiopathic VTE, as well as overall VTE in
men with hypogonadism.
As mentioned by the authors, this study is
limited due to being based on retrospective
claims data. Certain comorbidities increasing risk
for VTE were not available for inclusion in the
analysis. Additionally, testosterone deﬁciency was
not conﬁrmed in the treated cohort prior to
treatment; the need for treatment and levels of
testosterone during treatment were not analyzed.
Regarding the potential increased risk of VTE,
one theorized mechanism is that testosterone
induces polycythemia, which increases blood
viscosity [3]. Interestingly, another recent
nonrandomized single-center open-label registry
study supports the possibility that longer dura-
tion testosterone replacement therapy (TRT) in
testosterone deﬁcient males may decrease the
prevalence of anemia, improve lipid proﬁles, and
may actually lower the overall risk for VTE [4].
When considering the effects of TRT adminis-
tration, one must consider the overall need and
goals of therapy, duration of treatment, and the
patient’s comorbidities. Much remains unclear
regarding the mechanisms by which TRT may
alter risk factors and who is at higher risk for
these potentially morbid or fatal side effects.
Recent data on the possible risks of TRT are
insightful and thought provoking; however,
further long term randomized control trials of
properly selected patient groups are needed to
determine if TRT does truly alter the risk of
VTE.
Theodore R. Saitz, MD
Department of Urology
Oregon Health & Science University
Portland, OR, USA
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Female Basic Science
Comment on: Pelvic nerve injury negatively
impacts female genital blood flow and induces
vaginal fibrosis—implications for human
nerve-sparing radical hysterectomy. F
Castiglione, A Bergamini, M Albersen, JL
Hannan, TJ Bivalacqua, A Bettiga, F Benigni, A
Salonia, F Montorsi, P Hedlund. BJOG
2015;122:1457–65.
Since the development of the anatomic approach
to radical prostatectomy (RP) by Dr. Patrick
Walsh, nerve-sparing RP surgical techniques have
been used to preserve urinary and sexual function
in men with prostate cancer. Additionally, animal
models of cavernous nerve injury have been well
established and the mechanisms of nerve injury
can be elucidated to preserve neuronal and erectile
function. In women, cervical cancer is the second
most common cancer and is most frequently
treated by radical hysterectomy (RH). Similar to
RP, women commonly suffer from bladder,
anorectal, and sexual dysfunctions due to pelvic
autonomic nerve damage following RH. More
recently, a greater understanding of the
neuroanatomy of the autonomic pelvic plexus that
supplies the urogenital tract exists in women and
nerve-sparing RH or individually tailored surgery
to preserve nerve function is commonly per-
formed. These reﬁned surgical techniques have
improved the quality of life of women undergoing
RH; however, urogenital dysfunction persists in
some patients. The mechanism of urogenital dys-
function in women following RH remains to be
elucidated.
This study is the ﬁrst to develop an animal
model of female pelvic nerve injury to address the
mechanisms of nerve-sparing RH on female
genital blood ﬂow. Authors performed two differ-
ent types of unilateral pelvic nerve injury in young
female rats: (1) a pelvic nerve crush (PNC) and (2)
a clock-nerve crush (CNC) in which the pelvic,
hypogastric, and vesicogenital branches of the
pelvic plexus supplying the urinary bladder and
vagina were crushed. Interestingly both PNC and
CNC injuries resulted in similarly impaired nerve-
mediated increases in clitoral and vaginal blood
ﬂow compared with stimulation of the uncrushed
nerve at 3 and 10 days after injury. The
histopathology in the animal model was compa-
rable with that seen in patients following RH. The
distal vagina appeared ﬁbrotic as evidenced by the
increased collagen types I and III and decreased
alpha smooth muscle actin conﬁrmed by
immunoﬂuorescence staining and Western blots.
Neuronal nitric oxide synthase, which is respon-
sible for the production of nerve-mediated release
of nitric oxide (NO) during sexual responses, was
decreased in vaginal tissue from injured rats while
endothelial nitric oxide synthase remained
unchanged.
This study is signiﬁcant in that it is the ﬁrst to
describe a female model of pelvic nerve injury to
evaluate impaired genital blood ﬂow. Similar to
the male animal model of RP, it appears that
impaired vaginal blood ﬂow is a result of decrease
in the number of nitrergic nerves that are respon-
sible for the release of NO. In the penis,
impaired NO release leads to a hypoxic environ-
ment promoting the development of ﬁbrosis
and erectile dysfunction. The increased collagen
deposition and impaired NO release in the vagina
may lead to decreased smooth muscle compli-
ance, decreased vaginal engorgement, and lubri-
cation. This model provides some insight into
the etiology of sexual dysfunction following RH
and will help to discover novel therapeutic targets
in the setting of neuropraxia-induced female
sexual dysfunction.
Johanna L. Hannan, PhD
Department of Physiology
Brody School of Medicine
East Carolina University
Comment on: The role of oxytocin in male and
female reproductive behavior. JG Veening, TR
deJong, MD Waldinger, SM Korte, B Olivier. Eur
J Pharm 2015;208–28.
It has been known for decades that oxytocin is
linked to various aspects of sexual and reproduc-
tive behavior. Oxytocin is released during orgasm
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in men and women, and induces uterine contrac-
tions and lactation with a profound effect on
maternal behavior. Over the past 20 years, the role
for oxytocin has expanded to include social behav-
iors including enhancing trust and fear reduction.
The mechanisms by which oxytocin modulates
neural pathways to produce various physiological
and psychological changes are still unclear, partly
because of the difﬁculties in identifying and hence
mapping the location of central receptors and how
the central oxytocin system changes during devel-
opment and in response to other hormones such as
estrogen, progesterone, and prolactin.
In this review, Veening and colleagues provide
an up to date summary of the role of oxytocin in
female sexual and maternal behavior as well as its
role in male sexual responses. A critical under-
standing of the function of oxytocin is explored
based on the paraventricular hypothalamic nucleus
(PVH), the supraoptic hypothalamic nucleus, and
accessory hypothalamic neurons that produce
oxytocin and their neuronal projections to the pos-
terior pituitary where it is released into the general
circulation. In addition, the neural projections of
the PVH to the olfactory bulbs, limbic system,
brainstem, and spinal cord regions that control
various aspects of social and sexual behaviors are
discussed in the context of emotional and sexual
desire, copulatory responses, and orgasm in
females and males as well as the interrelationship
of aggressive behavior and parental care on social
and sexual behaviors.
Another recent report [1] demonstrates how
tyrosine hydroxylase containing neurons in the
periventricular nucleus of the hypothalamus
directly activates the release of oxytocin from
neurons in the PVH to enhance maternal behavior
in female mice and reduce aggressive behavior in
male mice.
Therefore, basic research supports the general
conclusion that oxytocin facilitates social behav-
iors by reducing associated anxiety and enhancing
positive peripheral excitatory/genital feedback.
The use of oxytocin as a treatment for various
clinical CNS disorders has been challenging
because oxytocin and its antagonists do not
readily pass through the blood–brain barrier.
However, studies in both animal models and
humans recently acknowledged that intranasal
administration of oxytocin modulates central
nervous system (CNS) function, which provides a
valuable tool for further understanding of the
role of oxytocin in sexual behavior and provides
treatments for CNS disorders such as depression
and schizophrenia.
Oxytocin enhances social and sexual behaviors
by direct action on peripheral target organs and
brain regions and indirectly by activating neural
networks that modulate the behaviors. Further
understanding on the mechanisms by which the
oxytocin system is regulated during development
and the nature of environmental, hormonal, and
genetic factors and their modulation of oxytocin
production and release is required to more clearly
understand the complex nature of oxytocin in
reproductive and sexual behaviors.
Lesley Marson, PhD
Adjunct Professor,
Department of Urology
UNC Chapel Hill
NC, USA
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Comment on: Flibanserin treatment increases
appetitive sexual motivation in the female rat.
H Gelez, J Greggain-Mohr, JG Pfaus, KA Allers,
F Giuliano. J Sex Med 2013;10:1231–9.
This preclinical study reports the ﬁndings from
two separate laboratories that independently con-
ducted research in female rats to assess the dose–
response effects of acute and chronic ﬂibanserin on
female sexual behavior. This work demonstrated
the ﬁrst evidence that chronic, but not acute,
ﬂibanserin treatment augmented appetitive sexual
behaviors in ovariectomized, hormonally primed
female rats and provides evidence that solicitations
in the female rat can be a predictive animal model
of human female sexual desire. Additional studies
performed in female marmoset monkeys suggested
the drug increases social–sexual behavior [1,2].
Prior animal studies by Allers and colleagues dem-
onstrated that ﬂibanserin differentially modulates
catecholaminergic and serotonergic activity in dis-
tinct brain areas to modulate sexual behavior [3,4].
In addition, Gelez et al. reported that ﬂibanserin
speciﬁcally activates neurons in brain regions,
mesolimbic dopaminergic pathways and hypotha-
lamic areas, involved with sexual motivation [5].
These studies provide basic science research
supporting the use of ﬂibanserin (Addyi™),
230 Sex Med 2015;3:227–234
recently approved by the FDA for the treatment of
premenopausal women with acquired, generalized
hypoactive sexual desire disorder. Flibanserin
(originally BIMT-17) is a mixed 5-HT1A agonist/
5-HT2A antagonist that was originally developed
for the treatment of major depressive disorder and
had been tested extensively in animal models of
depression and anxiety. Many clinical trials in
women have shown that ﬂibanserin helps improve
low sexual desire. This comment references some
of the animal studies that were performed and
shows evidence of how animal studies can support
clinical studies during drug development.
Lesley Marson, PhD
Adjunct Professor,
Department of Urology
UNC Chapel Hill
NC, USA
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Female Clinical Science
Comment on: Prevalence of sexual dysfunction
after risk-reducing salpingo-oophorectomy.
PE Tucker, MK Bulsara, SG Salﬁnger, JJ Tan, H
Green, PA Cohen. Gynecol Oncol 2015 Nov 3.
pii: S0090-8258(15)30174-8.
The authors conducted a cross sectional study of
women who underwent a risk-reducing salpingo-
oophorectomy (RRSO) to determine the preva-
lence of sexual problems and complaints in this
postsurgical population. In addition, several factors
were examined including hormonal proﬁles to
discern which facets maybe associated with sexual
health and wellness. The study population was in a
tertiary gynecologic oncology unit, and subjects
were obtained from January 2009 to October 2014.
Detailed questionnaires that used validated sexual
health indices and associated sexual distress were
utilized. Relationship satisfaction, sexual self-
image, body image, and quality of life consider-
ations were also assessed. Patients had blood draws
for serum testosterone and free androgen index.
Fifty-eight percent or 119 out of 206 women par-
ticipated in the study. The mean age of the partici-
pants was 52 years. Female sexual disorders were
rather prevalent with hypoactive sexual desire dis-
order (HSDD) having an incidence of 73%. Other
common complaints included changes in quality
and quantity of vaginal lubrication, decline in
overall sexual satisfaction, and painful intercourse.
Twenty-ﬁve percent of the women who underwent
a risk-reducing bilateral salpingo-oophorectomy
(RRBSO) complained of change in orgasmic
quality (intensity and/or latency).
Women who used minimally absorbed local
vaginal estrogen products and those who had
lowered body pain, as well as those who reported
relationship fulﬁllment and contentment had a
lowered likelihood of reporting sexual problems.
Menopausal status, prior history of breast cancer,
and removal of the uterus (hysterectomy) were
not correlative with sexual dysfunction. Interest-
ingly serum testosterone and free androgen index
were not associated with sexual problems.
The data in this article are corroborated with
other published articles, which demonstrate a
linkage of RRBSO to sexual problems in the post-
operative period that are linked to changes in
quality of life.
With the increased popularity of Angelina
Jolie’s decision to undergo genetic testing, and
subsequently undertake risk-reducing interven-
tions, clinicians have seen an increase in both
genetic testing and patient requests for prophy-
lactic surgical interventions to potentially reduce
cancer. Surgical intervention not only carries a
risk during the operative period and during the
recovery time but also has far reaching implica-
tions to the woman’s overall quality of life and
sexual vitality.
Women must be counseled accordingly regard-
ing the sexual implications of RRBSO and inter-
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ventions such as minimally absorbed local vaginal
estrogen should be offered in anticipation of sexual
problems. Perhaps the utility of a pre-operative
sexual medicine consultation should be assessed.
Given the high prevalence of sexual dysfunction
after RRBSO, aggressive evaluation and diagnos-
tics interventions should be implemented when
clinical suspicion of sexual problems exists. Since
sexual problems have far reaching implications on
overall health and quality of life, assessment and
referral for sexual health treatment from a special-
ist should be a part of the comprehensive manage-
ment paradigm.
Michael Krychman, MD
Southern California Center for Sexual Health and
Survivorship Medicine
Female Mental Health
Comment on: Sexual esteem in emerging
adulthood: Associations with sexual behavior,
contraception use, and romantic relationships.
MK Mass, ES Lefkowitz. J Sex Behav
2015;52:795–806.
Sexual health practitioners/educators working
with women can beneﬁt from a better understand-
ing of the emotional/mental side of sexual devel-
opment. Understanding the development of sexual
health behaviors and their associations with the
romantic contexts of those behaviors and sexual
esteem can inform sexual health education
program designers to create educational programs
that address not only risk reduction but promote
consensual, emotionally fulﬁlling, and more plea-
surable sex. This study aimed to explore these
associations in an emerging adult population,
which is when many people’s sexual experiences
seem to accelerate.
The researchers collected data using online
surveys and the information gathered was part of a
larger longitudinal study at a university in the
United States. Data collection started in the stu-
dents ﬁrst year of college and the researchers fol-
lowed the participants over 5 semesters. The ﬁnal
analytic sample consisted of 518 students, 56% of
which were female, 97.7% of which were hetero-
sexual, and with a mean age of 20.43 (SD = .41)
years old. The researchers used two separate linear
regression models with sexual esteem as the
outcome.
The results of the study indicated that male
and female participants who had oral sex more
frequently, recently had more oral and penetrative
sexual partners, and spent more time in romantic
relationships tended to have higher sexual esteem
than those who did not. Interestingly, sexually
active male emerging adults who never used con-
traception during recent penetrative sex tended to
have higher sexual esteem than those who did not
use it, whereas female emerging adults who never
used contraception tended to have lower sexual
esteem than those did use it. This information can
be very useful for sexual health practitioners
wanting to promote safe, consensual, and pleasur-
able sex in women.
Rose Hartzell-Cushanick, PhD, EdS, CHES, LMFT
Sex Therapist, San Diego Sexual Medicine
AASECT Certiﬁed Sexuality Therapist & Educator
Sexual Pain
Comment on: Depression and posttraumatic
stress disorder among women with vulvodynia:
Evidence from the population-based woman to
woman health study. L Iglesias-Rios, SD
Harlow, BD Reed. J Womens Health (Larchmt)
2015 Jul;24(7):557–62.
Vulvodynia, or idiopathic vulvar pain, may be
exacerbated by psychological factors such as
anxiety and fear of pain. However, most studies
examining these factors are characterized by rela-
tively small clinical samples, biased in terms of
higher levels of distress. This multiethnic
population-based study involving 1795 women
corrected for this limitation and showed that those
who screened positive for depression had a 53%
higher prevalence of having vulvodynia, and those
who screened positive for post-traumatic stress
disorder (PTSD) had more than a twofold increase
in the prevalence of having vulvodynia. Thus,
depression and PTSD were independently associ-
ated with the prevalence of vulvodynia.
This is the ﬁrst study to show that PTSD
increases the odds of reporting vulvodynia.
PTSD is a debilitating psychiatric disorder that
may develop after unresolved trauma, such as
childhood sexual abuse (CSA). It is characterized
by intrusive re-experiencing of the traumatic
event, avoidance behaviors, hypervigilance, and
emotional numbing, as well as by activation in
the physiological and neuroendocrine systems. A
population-based study showed that women with
vulvodynia had almost three times the odds of
reporting experiences of severe childhood physi-
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cal and sexual abuse when compared with women
without vulvodynia [1]. PTSD is a common con-
sequence of CSA. Although cross-sectional, ﬁnd-
ings of this study suggest that one of the
pathways by which CSA may lead to the devel-
opment of vulvodynia is through the modiﬁcation
of immunoinﬂammatory response mechanisms
such as those involved in PTSD, as a growing
body of evidence supports the role of inﬂamma-
tion in vulvodynia [2]. This study thus lends
support to a biopsychosocial conceptualization of
vulvodynia.
Findings also have implications for treatment.
By providing strong support for the involvement
of PTSD and depression in vulvodynia, results
suggest that medical interventions may need to
be combined with psychological approaches such
as cognitive-behavioral therapy, in order to target
the cognitive, affective, and behavioral correlates
of vulvodynia, simultaneously with their
neuroinﬂammatory counterpart, for optimal
patient care.
Sophie Bergeron, PhD
Department of Psychology
University of Montreal
Quebec, Canada
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LGBT Studies
Comment on: Care of the transgender patient:
A survey of gynecologists’ current knowledge
and practice. CA Unger. J Womens Health
(Larchmt) 2015 Feb;24(2):114–8.
In general, clinicians are poorly equipped to meet
the healthcare needs of transgender people. In an
anonymous survey of US gynecologists’ prefer-
ences and knowledge base with regard to
transgender healthcare, Unger [1] sought to
assess provider experience and practice environ-
ment, education about transgender health prac-
tices, personal experience with transgender
patients, and knowledge base regarding current
recommendations for the care of gender minority
patients. Of the 141 gynecologists that responded
(40.1% response rate), 80% had not received
training in residency on the care of transgender
patients and time in practice was not associated
with having learned about transgender care. Only
around one-third reported being comfortable
caring for trans men (who may retain the internal
genitalia of their birth) and trans women; around
60% did not know the recommendations for
breast cancer screening for trans women.
John Dean, MBBS, FRCGP, FECSM
Specialist in Sexual Medicine
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Comment on: Diagnosis of prolactinoma in
two male-to-female transsexual subjects fol-
lowing high-dose cross-sex hormone therapy.
FS Cunha, S Domenice, VL Camara, MH Sircili,
LJ Gooren, BB Mendonca, EM Costa. Andrologia
2015 Aug;47(6):680–4.
Cunha et al. [1] report two new cases of
prolactinoma in transwomen, aged 41 and 42
years. Both had very high serum prolactin levels
and the diagnosis of prolactinoma was conﬁrmed
by imaging techniques; both responded well to
treatment with cabergoline. This brings to ﬁve the
total number of prolactinomas associated with
supraphysiological doses of estrogens that are
described in the literature.
John Dean, MBBS, FRCGP, FECSM
Specialist in Sexual Medicine
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Comment on: Body image dissatisfaction and
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Witcomb et al. [1] explored the high levels of body
dissatisfaction reported in the trans population and
its association with eating disordered behaviors.
Sex Med 2015;3:227–234 233
They assessed eating disorder risk by comparing
200 trans people, 200 people with eating disorders,
and 200 control participants’ scores on three
subscales of the Eating Disorders Inventory-2
(EDI-2), and explored dissatisfaction among trans
participants using the Hamburg Body Drawing
Scale (HBDS). As might be expected, participants
with eating disorders scored higher than trans or
control groups on all EDI-2 measures; trans indi-
viduals had greater body dissatisfaction than
control participants; and, importantly, trans men
had comparable body dissatisfaction scores with
eating-disordered men. Drive for thinness was
greater in women (both natal and trans) compared
with men. In relation to HBDS body dissatisfac-
tion, both trans men and trans women reported
greatest dissatisfaction, not only for gender-
identifying body parts but also for body shape and
weight. The authors conclude that trans males
may be at particular risk for eating-disordered psy-
chopathology and other body image-related
behaviors.
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Comment on: Quality-of-life measurement:
Assessing the WHOQOL-BREF scale in a
sample of high-HIV-risk transgender women
in San Francisco, California. HM Thompson,
SL Reisner, N VanKim, H Fisher Raymond. Int J
Transgenderism 2015;16(1):36–48.
Research in transgender healthcare is hampered by
the lack of validated measures for use in these
populations. In the International Journal of
Transgenderism, Thompson et al. [1] assess the psy-
chometric properties of the WHOQOL-BREF in
a sample of HIV-positive trans women in San
Francisco. This instrument consists of 24 items,
encompassing four domains: physical health, psy-
chological health, social relationships, and envi-
ronmental conditions. It extends beyond
assessment of health alone and captures important
aspects of responders’ daily social contexts. The
authors conclude that it is an acceptable, reliable,
and valid measure of quality of life for research
with transgender women.
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